





The scientific world is still
searching for appropriate candidate
vaccines for malaria and HIV
infection. Despite the availability
and effectiveness of many vaccines,
the benefits to a country is highly
dependent on a viable and
sustainable health system which
include adequate financing,
dynamic and motivated workforce,
strong partnerships and effective
community participation. If well
deployed, available vaccines as
elucidated in this discourse can
accelerate the achievements of the
Millennium Development Goals in
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Abstract Vaccines are arguably
the most important public health
tools available today. Since the
successful eradication of small-
pox with the use of the vaccine,
many vaccines have become
available to man. Of great
importance to public and child
health are the vaccines against the
so-called six killer diseases of
childhood- measles, pertussis,
diphtheria, tetanus, tuberculosis
and poliomyelitis. In the last 2
decades, effective vaccines against
the major causes of pneumonia,
another childhood killer, have
become available. Data from many
parts of the world including
African countries have shown the
benefits of the and
vaccines.
pneumococcal
Haemophilus influenzae type b
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Vaccines and immunization: The past,





: Protection from microbes recognized as
foreign. The immune system is composed of organs
& specialized cells that protect the body by
identifying harmful substances & destroying them
using anti-bodies, and other specialized substances
& cells.
: Following antigenic
challenge antibodies, specific helper and effector T
lymphocytes including those producing cytokines
and killer T cells are produced.
: Any preparation intending to produce
immunity to a disease by stimulating the production
of antibodies. Can prevent or ameliorate the effect of
infections by many pathogens. Most common
method of administration is by injections, but can be





: Any vaccine for which the
development was foreseeable with the next decade.
: A population based measure of
protection rather than a measure of antibody
production in an individual. This is represented by the
equation below:
Rate of illness in unvaccinated population Rate of
illness in vaccinated population
Rate of illness in unvaccinated population
: Is that portion of disease
burden that could be prevented by immunization of
entire target population with hypothetical vaccine
100% effective against the strain included in it.
: Is the administrations of antigenic
materials to produced immunity to a disease. It was






Consist of virus particles which
are grown in culture and then killed using heat or
formaldehyde. These particles are destroyed but
capsid proteins are intact enough to be recognized and
remembered by immune system, thus evoking a
response. It is non-replicating, with less interference
from circulating antibodies. Requires more doses and
causes a mostly humoral immune response. The
antibody titre diminishes with time.
Examples of inactivated vaccines include:
Viral- poliomyelitis (salk) hepatitis A, Rabies,
influenza
Bacteria- pertussis, typhoid, cholera, plague,
anthrax
Fractional subunit  hepatitis B, acellular
pertussis, human papilloma virus
Toxoids  diphtheria, tetanus
Polysaccharide  pneumococcal, meningococcal,
salmonella typhi
Conjugate polysaccharide- Hib, pneumococccal,
meningococcal
Recombinant  hepatitis b , human papilloma
virus, influenza
Immune globulin  homologous pooled
antibody.hepatitis A, measles
Homologous human hyperimmune globulin.
PEP hepatitis B, rabies, tetanus, varicella
Heterologous hyperimmune serum(antitoxin):
antitoxin derived from injecting animals with
the organism such as for botulism, diphtheria
Monoclonal antibodies derived from the clone
of antibody producing cells, e.g. RSV.-
Palivizumab
Produced by modifying a
naturally occurring organism (wild) usually by
repeated culturing, and retains the ability to
replicate and produce immune response similar to
natural infection. Circulating antibody may interfere
with response. Provides long lasting immunity, and
one dose usually suffices. Examples of live
attenuated viruses- poliomyelitis, measles, rubella,
mumps, rabies, varicella, yellow fever, rotavirus,
influenza. Examples of live attenuated bacteria-
Bacille Calmette Guerin, typhoid.
It is a proven tool for controlling & eliminating
life threatening infectious diseases (over 2million
deaths per year).
Avoids suffering, disability and death.
One of the most cost effective health



























: A process of artificial induction of
immunity in an effort to protect against infectious
disease.
: Induces in the recipient a
degree of immunity similar to that achieved from the
natural infection, and is able to prevent clinical
disease. Produced by individual immune system and
the immunity are usually long lasting.
: Is the administration of
exogenously preformed antibodies, and the immunity
is temporary. Commonest source is that obtained
transplacentally. Others are blood and blood
products, immune or hyper immune globulin &
animal antitoxin.
: This is made from purified toxins produced
by infective agent, attenuated to neutralize this toxic
effect without reducing antigenicity e.g tetanus
toxoid, diphtheria toxoid.
: Ability of vaccine to elicit a particular
response at a certain dose in other to work. It is a
measure of a vaccine activity in biological system.
A scientifically designed and executed
investigation of the effects of a drug (or vaccine)
administered to human subjects. The goal is to define
the safety, clinical efficacy, and pharmacological
effects (including toxicity, side effects ,
incompatibilities, or interactions) of the drug.
: Each study subject is randomly
assigned to receive either the study treatment or a
placebo.
: The subjects involved in the study do not know
which study treatment they receive. If the study is
double-blind, the researchers also do not know which
treatment is being given to any given subject.
: Allows additional insurance
against bias or placebo effect. In this kind of study, all
patients are given both placebo and active doses in
alternating periods of time during the study.
: The use of a placebo (fake
treatment) allows the researchers to isolate the effect
of the study treatment. Open-label means that both
the participants and the scientists know what is given.
: Is a packaging system that can help deliver the
vaccine more effectively into the correct part of the
body or into the correct cell to create an immune
response.
: Consists of some extra genes added into the
vector.
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This process, known as "variolation," took a variety
of forms. One form consisted of removing pus and
fluid from a smallpox lesion and using a needle to
place it under the skin of the person to be protected.
The second involved peeling scabs from lesions,
drying and grinding them to a powder, and letting an
uninfected person inhale this powder.
The third method involved picking up a small amount
of the scab powder with a needle and then using the
needle to place the powder directly into the
individual's veins. Although the effects of variolation
varied, ranging from causing a mild illness in most
individuals to causing death in a few, the mortality
and morbidity rates due to smallpox were certainly
lower in populations that used variolation than in
those that did not.
Edward Jenner noticed a relationship between the
equine disease known as "grease" and a bovine
disease known as "cow pox. “At the same time,
Jenner was interested when a milkmaid told him that
she could not catch smallpox because she had had
cowpox. Jenner noted that there were many people
like the milkmaid - people who milked cows and who
did not get smallpox even when exposed repeatedly.
With this in mind, Jenner undertook a daring
experiment in 1796:
It soon became clear that Jenner's experiments had
paid off, and that intentional infection with cowpox
protected people from much more serious infection
with smallpox. As a result, within a few years
thousands of people protected themselves from the
deadly smallpox disease by intentionally infecting
themselves with cowpox. Jenner's process came to be
called "vaccination," after "vacca," the Latin word for
cow, and the substance used to vaccinate was called a
"vaccine."
Now, over 200 years later, we have progressed from a
time when vaccination was a rare event, and Jenner's
theories about vaccination were not widely accepted,
to the late 1900s when vaccines are so commonplace
that most children receive multiple vaccinations
before they reach their first birthdays. The result of
such widespread vaccination has been a marked
decrease in diseases which once ravaged the world's
population.
Below is the timeline of some vaccines:
1721- Introduction into Britain from Turkey by
Lady Wortley Montagu of inoculation of material
from smallpox patients into healthy persons
( )
1796 -First vaccination against smallpox
performed by Jenner






accessible to most hard to reach & vulnerable
population.
Can be delivered effectively through outreach
activities.
Ease strain on health care system, and money is
saved for use in other health care services.
Has clearly defined target group.
Does not require any major change in life style.
This was introduced in Nigeria in 1979. From 1979
1997, the program was known and called Expanded
Programme on Immunization (EPI). To give a
national outlook and show Federal Government
commitment, the Federal Govt. established an agency
called NPI under Decree 12 inAugust 1997. This is to
effectively control the occurrence of all vaccine
preventable diseases through immunization and
provision of vaccine and other consumable. Focus is
on prevention, control & eradication of the following
vaccine preventable disease in Nigeria i.e.
tuberculosis, measles, diphtheria, pertussis, neonatal
tetanus, cerebrospinal meningitis, yellow fever and
polio. These are targeted through immunization
service delivery and this is done by administration of
vaccine to susceptible target.
NPI aim the following group of people: Children of
age ≤ 11month, all pregnant women and women of
reproducing age group.
Birth  OPV , HBV , BCG
6weeks OPV , DPT , HBV
10weeks  OPV , DPT
14weeks  OPV , DPT , HBV
9months  Measles, Yellow fever, Vitamin A
15 months- Vitamin A
In pregnant women, or women in reproducing age
group:
Tt1 at 1 contact no protection
TT2  4wks later 80% protection for 3years
TT3 6mths later 95% protection for 5 years
TT4 1year later or in subsequent pregnancy
99% protection for 10 years
Tt5 1 year later or in subsequent pregnancy 99%
protection for life
Long before the causes of disease were known and
the processes of recovery were understood, the
Chinese trial of exposing uninfected individuals to
















National Programme on Immunization (NPI)
Immunization schedule in Nigeria











Maternal and Neonatal Tetanus
Hepatitis B:
Hepatitis B vaccine
Maternal and neonatal tetanus (MNT)
Global coverage of infants with three doses of
polio vaccine in 2008 was 83%, but in 1990 it was
75%. Reported number of polio cases in 2008: 1730
confirmed polio cases (including 1651 wild virus
confirmed cases) as against 350 000 in 1988. The
number of polio-endemic countries in 2008 was 4, as
against 125 in 1988.
Global coverage of children by their second
birthday with one dose of measles containing vaccine
in 2008: 83%, while the global coverage of children
by their second birthday with one dose of measles
containing vaccine in 1990: 73%. Number of
countries with a second dose of measles vaccine in
routine immunization schedule: 133 (69% of 193
countries). Number of estimated measles deaths in
2007: 197 000 [141 000 - 267 000], of which 177 000
[126 000 - 240 000] were under age five.
: The number of
countries that had not yet eliminated MNT in 2008
was 46. Number of women living in high-risk areas
protected with at least two doses of tetanus toxoid
vaccine given during supplementary immunization
activities (1999-2008): 90 million.
Global coverage of infants with three
doses of hepatitis B vaccine in 2008 had increased to
69% from 1% in 1990.
Increasing uptake of new and underused vaccines
: The use of this vaccine for
infants was introduced nationwide in 177 countries
(including in parts of India and the Sudan) by the end
of 2008, up from 171 countries in 2007. Global
hepatitis B vaccine coverage is estimated at 69% and
is as high as 89% in the Western Pacific and 88% in
the Americas. Coverage in the South-East Asia
Region increased from 29% to 41%, over the same
period. Haemophilus influenzae type B (Hib) vaccine
was introduced nationwide in 136 countries
(including in parts of Belarus, Pakistan and the
Sudan) by the end of 2008, from 115 countries in
2007. Global coverage with three doses of Hib
vaccine is estimated at 28% in 2008, reaching 90% in
the Americas, but only 4% in the Western Pacific
Region.
: The vaccine
to prevent MNT was introduced as part of routine
immunization programmes in over 100 countries by
the end of 2008. Vaccination coverage with at least
two doses of tetanus toxoid vaccine or tetanus-
diphtheria toxoid vaccine was estimated at 74% in
2008 and an estimated 81% of newborns were
protected against neonatal tetanus through
immunization. As of December 2008, maternal and
neonatal tetanus persist as public health problems in


















1885 -Pasteur developed rabies vaccine
1895 -Yersin produced plague vaccine
1898 -Almroth Wright developed typhoid
vaccine
1921 -Calmette and Guérin introduced BCG
vaccine
1923 -Ramon developed diphtheria toxoid
1927 -Ramon and Zoeller developed tetanus
toxoid
1940 -National immunization campaign
launched in Britain by Ministry of Health; did
not become widespread until 1942
1954 - (killed) polio vaccine introduced
1957 - (live) polio vaccine introduced
1960 -Measles vaccine developed by Enders
1962 -Rubella vaccine developed by Weller
1967 -Jeryl Lynn strain of live attenuated
mumps vaccine licensed in the US
1968 Meningococcal (type C) vaccine
developed. Measles vaccine introduced on a
national scale in Britain
1970 -Rubella vaccine became available in
Britain
1981 -Hepatitis B vaccine licensed in US
1988 -Measles, Mumps, Rubella (MMR)
vaccine introduced into Britain
1992 -Haemophilus influenzae b (HiB) vaccine
introduced into Britain
Based on the World Health Organization
(WHO)/UNICEF global estimates for 2008, trends
related to global vaccination coverage continue to be
positive. Immunization currently averts an estimated
2.5 million deaths every year in all age groups from
diphtheria, tetanus, pertussis (whooping cough), and
measles. More children than ever before are being
reached with immunization. In 2008, an estimated
106 million children under the age of one were
vaccinated with three doses of diphtheria-tetanus-
pertussis (DTP3) vaccine.
More countries achieve high levels of vaccination
coverage. Three regions: the Americas, Europe and
Western Pacific maintained over 90% immunization
coverage. The number of countries reaching 90% or
more immunization coverage with DTP3 vaccine in
2008: 120 countries compared to 117 in 2007. The
number of countries reaching over 80% DTP3
coverage in 2008: 151 countries in 2008 compared to
150 in 2007.
: Global coverage of infants in 2008 with DTP3
vaccine was 82%, while in 1990 DTP3 vaccine
coverage was75%. Estimated number of children






Firstly the primary health care services are highly
ineffective and have deteriorated due to the lack of
investment in personnel, facilities and drugs, and
because of poor management of the existing
resources. A formerly strong primary health care
system in northern Nigeria has weakened over many
years. Polio outbreaks, rumors on the safety of the
polio vaccine, and subsequent campaigns disrupted
rout ine immuniza t ion services . Rout ine
immunization services are either no longer available
or irregular; limited resources for health services and
gaps in vaccine storage and distribution add to the
challenge of increasing immunization coverage.
There is also a problem of confidence and trust by the
public in the health services resulting from the poor
state of the facilities and low standards of delivery.
These problems have been exacerbated by “vertical”
interventions undertaken by outside agencies which
undermined the capacity of the local service
providers to implement sustainable programmes. At
the family / community level there is a low demand
for immunization due to a lack of understanding of its
value.
A number of new vaccines with major potential for
controlling infectious diseases have just been
licensed or are at advanced stages of development.
Among the illnesses targeted are rotavirus diarrhoea,
pneumococcal disease, malaria and HIV which
together kill more than a million children each year,
most of them in developing countries. Vaccine
development proceeds through discovery, process
engineering, toxicology and animal studies to human
Phase I, II, and III, and IV trials. The process can take
more than 10 years, depending on the disease.
Phase I  focus is on safety, involving small
groups of people(20-100)
Phase II  moderate-sized "target" populations
(persons close to the age and other xteristics for
whom the vaccine is intended) to determine
both safety and the stimulation of immune
response (20-300)
Phase III -  large target populations (30-3000)to
establish whether a vaccine actually prevents a
disease as intended (efficacy) ,
Phase IV trial is also known as post marketing
surveillance trial. It involves the safety
surveillance (pharmacovigilance), and ongoing
technical support of a drug after it receives
permission to be sold.










Introduced in 31 countries
(including five countries where the vaccine was
partially introduced) by the end of 2008, up from 20
countries in 2007.
: Introduced in 19 countries
(including two countries where the vaccine was
partially introduced) by the end of 2008.
: Introduced in routine infant
immunization programmes in 34 countries and
territories out of the 44 at risk for yellow fever in
Africa and theAmericas.
The number of children
under one year of age who did not receive DTP3
vaccine worldwide: 23.5 million in 2008 compared to
23.9 million in 2007. Seventy percent of these
children live in ten countries: Chad, China,
Democratic Republic of the Congo, Ethiopia, India,
Indonesia, Iraq, Nigeria, Pakistan and Uganda.
More than 10 million deaths occur globally in
children age < 5, of which 24% are due to VPD. The
total number of children who died from diseases
preventable by vaccines currently recommended by
WHO, plus diseases for which vaccines are expected
soon is 2.5 million. Distribution is hepatitis B: 600
000, Hib: 363 000, pertussis: 254 000, tetanus: 163
000, others (polio, diphtheria, yellow fever): 36 000.
Estimated number of deaths in children under five
from diseases preventable by vaccines (excluding
measles) currently recommended by WHO is 890 000
as Hib: 363 000, pertussis: 254 000, neonatal tetanus:
128 000, tetanus (non-neonatal): 16 000, others
(polio, diphtheria, yellow fever): 19 000.
Estimated number of deaths in children under five
due to rotavirus and pneumococcus: 1.3 million, as
pneumococcal disease: 735 000, and rotavirus: 527
000.
Immunization rates in Northern Nigeria are some of
the lowest in the world. According to the 2003
National Immunization Schedule the percentage of
fully immunized infants on the States to be targeted
was less than 1% in Jigawa, 1.5% in Yobe, 1.6% in
Zamfara and 8.3% in Katsina.As a result thousands of
children are dying as victims of vaccine preventable
diseases. In many parts of the north, barely 10
percent of children receive all of their routine
vaccines. Coverage rates for the vaccine against
tetanus among women are equally low. Why?
Deaths due to vaccine-preventable diseases (VPD)
In Nigeria
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can spread rapidly from the tropics to the
industrialized world. Several diseases of
importance to the developing world are also
potential bioterrorism threats.
The emergence of public-private partnerships
(PPPs). PPPs are coordinated by nonprofit
organizations that raise money from the public
sector and use this money to leverage efforts by
both the public and the private sectors to develop
and produce affordable vaccines for the
developing world. PPPs are involved in
accelerating the development of vaccines against
malaria, tuberculosis and HIV. Examples of PPP
are the International AIDS Vaccine Initiative, the
AERAS Global TB Vaccine Foundation, the
Malaria Vaccine Initiative, and the Global
Alliance for Vaccines and Immunization (GAVI)
The emergence of high quality vaccine producers
and capable national regulatory authorities in the
developing world. In Brazil, Cuba, India and
Indonesia certain manufacturers have been
prequalified by the World Health Organization to
supply EPI vaccines for purchase by United
Nations agencies. Due to location and the
available market of selling vaccines, the void of
the increasing departure of the international
companies is being filled.
developed in1896, heat-killed,
phenol-preserved, injectable whole-cell, still licensed
in several countries despite its high reactogenicity.
Two new vaccines are currently licensed and widely
used worldwide, a subunit (Vi PS) vaccine given via
the intramuscular route, andTy21a- a live attenuated
S typhi strain given orally.
: Administered as one
dose (25g) via the IM/SC route. It is given to school-
aged children and protective for at least three years,
with a good safety profile. It is poorly immunogenic
in infants and not used in children less than 2 years of
age.
: The first live oral typhoid fever
vaccine, administered as enteric-coated capsules to
be swallowed every other day for one week. The
vaccine is protective for at least 5-7 years.
Rotavirus diarrhoea is a leading cause of severe
diarrhoeal disease and dehydration in infants and









The Vi polysaccharide vaccine
The Ty21a vaccine
Rotaviruses (RV) Vaccine








Falter in the gains of the EPI of the late 1980s. The
initial high worldwide coverage decreased from
80% to < 50% of infants receiving their third dose
of DPT, esp. in sub-SaharanAfrica.
Increasing divergence between vaccine products
used in the industrialized versus developing
worlds. This divergence include newer
generation vaccines, several vaccines and
vaccine formulations that had formerly been used
jointly in industrialized and developing country
populations ceased to be recommended in
industrialized countries.
Little incentive for the vaccine industry in the
industrialized world to develop new vaccines
against diseases that were largely limited to the
developing world, as industrialized world
markets are more lucrative.
The increasing stringency of regulations imposed
by national vaccine licensing authorities usually
result in an increase in the costs of clinical
development pathways for licensure of vaccine
candidates to hundreds of millions of dollars.
New generation vaccines would have to cost
dollars per dose in order for industry to recover an
adequate return on its investmentin contrast to the
pennies per dose cost of the traditional EPI
vaccine.
It had become increasingly common to find that
vaccines performed less well in developing
country populations than in populations residing
in the industrialized world. Trials of vaccines in
developing countries were needed before their
introduction in these settings, and trials in
developing countries - not a priority for large
producers in the industrialized world. If they were
undertaken, they were typically deferred for years
after vaccine licensure in industrialized
To overcome the disincentives to industry of
creating new vaccines for the developing world,
Governments in the industrialized world have
traditionally used 'push mechanisms. Push
mechanisms - aim is to lower the risks and costs to
industry of research and development, and
includes; providing grants for product
development, supporting the costs of clinical
trials, strengthening of field sites in developing
countries, providing research and development
tax credits and expediting the regulatory and
licensing process.
Increased funding- major contributors are
foundations. This is due to the increasing
recognition that infectious diseases are major
threats to global security, and infectious diseases
Opportunities for vaccine introduction
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Pneumococcal conjugate vaccines (PCV):
S. pneumoniae





PCV, Prevnar (Wyeth), is recommended for routine
use in children aged less than two years. It is
administered in a 3 doses schedule, and when
possible in combination with usual routine
vaccination, followed by a booster dose at 15-18
months. Alternatively, the vaccine can be
administered in a two-dose immunization schedule at
3 and 5 months of age, followed by a booster
immunization at 11-12 months of age. It contains
poly- or oligo-saccharides from seven
serotypes (4, 6B, 9V, 14, 18C, 19F and 23F), each
conjugated to genetically detoxified diphtheria toxin
CRM 197. Currently there are at least the PCV-10 and
PCV-13 being used mainly in the private sector and in
the high risk populations in Nigeria.
Infections by type b are
responsible for severe pneumonia, meningitis and
other invasive diseases almost exclusively in children
aged less than 5 years. It is estimated to cause at least 3
million cases of serious disease every year, and
approximately 386 000 deaths.
: The Hib conjugate vaccines
consist of preparations of polyribosylribitol
phosphate (PRP) (the capsular polysaccharide of
Hib) conjugated to a protein carrier PRP covalently
bound to a carrier protein. When conjugated, the
carrier protein induces a T-cell dependent B-cell
immune response to the polysaccharide. The Hib
vaccines currently licensed for use in infants consist
of PRPconjugated to a protein carrier as listed below:
the nontoxic mutant diphtheria toxin CRM 197
(oligosaccharide conjugate PRPCRM197),
tetanus toxoid (PRPT),
meningococcal outer membrane protein
(PRPOMP).
The vaccines are formulated either as single antigens
or as part of combination vaccines. Hib vaccines are
safe and efficacious even when administered in early
infancy. Liquid Hib vaccines are used directly from
the vial, whereas freeze-dried vaccines must be
reconstituted before administration, either with
diluent or with another vaccine that has been
specifically identified and indicated for this purpose
by the manufacturer, such as DTP.
Approximately 350500 million cases of malaria
occur annually, killing between one and three million
people, the majority of whom are young children in
sub-Saharan Africa. Ninety percent of malaria-










Human monovalent live attenuated RV strain,
Rotarix , given as a  2-dose monovalent oral
vaccine.
Pentavalent live bovine-human reassortant
vaccine, RotaTeq , a live-attenuated, 3-dose
oral vaccine. Part of national vaccination
programs in several countries, including USA.
A Phase III trial is ongoing in African countries
(Mali, Ghana, and Kenya) and concluded at the
end of 2009.
Lamb-derived monovalent live attenuated
strain, LLR, which is only being used in China.
Several countries have introduced the Rotarix and
Rotateq vaccines into routine immunization
programmes
*RotaShield vaccine was introduced in the USA ,
administered in a three dose schedule but
intussusception noted within two weeks after
administration of the first two doses of vaccine, thus
leading to its eventual withdrawal.
infection is a leading
cause of morbidity and mortality among children
worldwide and particularly in developing countries,
estimated that 10.6 million children less than 5 years
present with pneumococcal disease every year. There
are two types of vaccines currently licensed for use.
the pneumococcal polysaccharide vaccine (PPV),
based on purified capsular PS
pneumococcal conjugate vaccines (PCV),
obtained by chemical conjugation of the
capsular PS to a protein carrier.
The
PPV23 vaccine contains the purified capsular PS
from each of the 23 different S pneumoniae serotypes
that together account for 90% of cases of severe
pneumococcal disease in industrialized countries.
Two vaccines are currently manufactured,
Pneumovax 23 (Merck) and Pneumo 23
(Sanofipasteur).
A good antibody response is achieved following a
single IM injection in 60-80% of healthy adults and
normal children over two years of age. PPV23 is
unable to elicit immune memory, so that a second
dose of vaccine does not boost antibody levels. Also,
PPV23 does not provide protection against mucosal
infection, and is thus unable to reduce
nasopharyngeal carriage of pneumococci. It is poorly
immunogenic in less than 2 years old children and is























Demonstration of immunogenicity, efficacy and
safety in the local population
Cost effectiveness data (1 vaccine or
comparisons?)
Inform policy makers, opinion leaders and
Health Care Workers
Inform the community through proper and
sustained engagement and involvement
Immunization Systems Strengthening (ISS)
support performance/reward based system
New Vaccine Support (NVS)  vaccine provided
for 1 five years
Decrease costs of vaccines (local
production)
Develop easy to use vaccines (no cold
chain)
Decrease the number of dosages
Targeted vaccination
Who to vaccinate? Importance of
unvaccinated pockets? Importance of
differences between rural and urban?
Large Household vaccination: Vaccinees
chosen sequentially  from those households
with the largest number of susceptibles
Resources for introducing new vaccines and
sustaining their use in developing countries,
including Nigeria are still comparatively scarce. The
resources will probably not ever be sufficient to
support the use of all new generation vaccines of
potential public health utility. Wise use of these funds
demands several types of evidence to inform policy
decisions. Simplified, inexpensive and valid methods
for obtaining crucial data at the country level, such as
the burden and costs of disease is needed. There is a
need to create an intellectual framework via research
to synthesize diverse types of relevant evidence to
assess the comparative merits of alternative vaccines
and then communicated to policymakers. To reduce
childhood mortality we need action now, traditional
advocacy methods have been slow and small in effect.
Reproduced with kind permission of the department
of Paediatrics and Child Health of the University of
Ilorin Teaching Hospital, Iliorin Nigeria owners of
the Ilorin Paediatric Digest 2010.




Malaria vaccines are in the developmental phase, and
there are different strategies been developed based on
the life cycle of the Plasmodium spp.
Pre-erythrocytic vaccine strategies prevent infection
and/or reduce incidence and severity of disease. Aim
is to generate an antibody response that will
neutralize sporozoites and prevent them from
invading the hepatocyte, and/or to elicit a cell-
mediated immune response that will inhibit intra-
hepatic parasites.
Asexual blood-stage (erythrocytic) vaccine strategies
reduce disease incidence and severity. Aim is to elicit
antibodies that will inactivate merozoites and/or
target malarial antigens expressed on the RBC
surface, thus inducing antibody-dependent cellular
cytotoxicity and complement lysis; they also are
intended to elicit T-cell responses that will inhibit the
development of the parasite in RBCs : Sexual blood
stage (transmission blocking) malaria vaccines are
targeting gametocytes, gametes and/or zygotes. It
aims to prevent man to mosquito transmission.
The RTS, S vaccine is the first malaria vaccine
candidate to demonstrate that young children and
infants exposed to intense
transmission can be protected from infection and
malaria disease. Current malaria prevention
programs and national immunization programs need
to be strengthened in order to be prepared for the
introduction of malaria vaccines when approved by
regulatory authorities and recommended as an
additional anti-malaria tool.
Lack of disease burden data
Weak health systems and its attendant poor
logistics such as cold chain
Poor transportation and storage systems
Inadequate and poorly motivated health care
worker
Lack of political will
Barriers to use of “new” vaccines
Poor health financing
Weak community participation
Lack of sustainable partnerships
Generation of local burden of disease data
(disease surveillance systems, regional sentinel
sites) which can be used to create awareness




Barriers to Use of Existing Childhood Vaccines



















3. WHO/UNICEF Review of
National Immunization
4.   Coverage 1980-2008
NIGERIA JULY 2009
5.   Global and regional
immunization profile,
African Region, 2009.




2010 global summary -
country profile Nigeria.
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